In melanoma, mesothelioma, and breast cancer, TGFBI overexpression suppressed proliferation and malignant potential [65,66,67]; however, targeting TGFBI may be associated with an increased risk of chemo-resistance in these patients. Here, TGFBI is linked to melanoma.